Baird Medical to Showcase Innovations at ATA Annual Meeting
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a prominent developer in the field of microwave ablation (MWA) medical devices, is excited to announce its participation in the upcoming American Thyroid Association (ATA) Annual Meeting. As a leader in the medical device sector, Baird Medical recently expanded into the U.S. market following its achievements in obtaining U.S. FDA 510(k) clearances, enhancing its reach and impact in thyroid care.
Event Details
The American Thyroid Association’s Annual Meeting will take place from October 30 to November 3 at the Sheraton Grand Chicago Riverwalk. Baird Medical will be located at Booth 100, which is recognized as one of the largest exhibitor spaces at the event. This setting allows Baird Medical to present its latest advancements in MWA technology, emphasizing its significance in the realm of thyroid treatment.
Expo Theater Presentation
During the event, Baird Medical will also conduct a significant Expo Theater Presentation on November 2. This session is scheduled from 10:25 AM to 11:25 AM within the Exhibit Hall of the Chicago Ballroom. The presentation, titled "Latest Advancements in MWA for Thyroid Treatment," will feature prominent experts including Dr. Emad Kandil from Tulane University, Dr. Feng Than from Sun Yat-sen University, and Dr. Khadra Helmi from Houston Methodist Hospital. Attendees can expect to gain valuable insights and knowledge that highlight recent developments in microwave ablation technology.
Quotes from Leadership
In a statement, Haimei Wu, Co-Founder of Baird Medical, expressed enthusiasm about participating in the ATA Annual Meeting: "We are excited to participate in the ATA Annual Meeting and present our innovations in microwave ablation technology. This event is an excellent opportunity to engage with leading experts and foster meaningful relationships to advance thyroid care. We warmly invite all attendees to visit our booth and attend our Expo Theater Presentation to explore our cutting-edge MWA technology."
Significance of Participation
Baird Medical's involvement in the ATA Annual Meeting highlights its strategic expansion into the U.S. market, building on its recent listing on the Nasdaq exchange. The company's FDA clearance for its minimally invasive microwave ablation technology represents a promising alternative to traditional thyroid surgery. With over 150,000 thyroidectomies performed annually in the U.S., their innovative approach provides a safer, less invasive solution for patients dealing with benign thyroid tumors.
About the ATA Annual Meeting
The ATA Annual Meeting serves as a premier gathering for individuals interested in thyroid diseases. This conference provides invaluable opportunities for professional learning and collaboration through various formats, including lectures, interactive discussions, and abstract presentations.
About Baird Medical
Founded in 2012 and headquartered in Guangzhou, Baird Medical has quickly established itself as a leader in the microwave ablation sector, particularly in the treatment of both benign and malignant tumors. The company specializes in developing devices for thyroid nodules, liver cancer, lung cancer, and other conditions. Baird Medical stands out as the first company to receive the Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For additional information, individuals can learn more about the company's innovations and products.
Frequently Asked Questions
What is the main purpose of Baird Medical's participation in the ATA Annual Meeting?
The main purpose is to showcase their innovations in microwave ablation technology and engage with leading experts in thyroid care.
What can attendees expect at Booth 100 during the event?
Attendees can expect to see the latest advancements in MWA technology and learn about its impact on thyroid treatment.
Who will be featured in the Expo Theater Presentation?
Dr. Emad Kandil, Dr. Feng Than, and Dr. Khadra Helmi will present the latest advancements in MWA for thyroid treatment.
Why is microwave ablation a significant alternative for patients?
Microwave ablation offers a minimally invasive option for treating benign thyroid tumors, which can lead to safer outcomes compared to traditional surgeries.
When and where will the ATA Annual Meeting occur?
The ATA Annual Meeting will take place from October 30 to November 3 at the Sheraton Grand Chicago Riverwalk.
